Somatostatin bolus injection for post-ERCP pancreatitis prevention: a need for further study

Gastrointestinal Endoscopy

Volumn 67, Issue 1, 2008, Pages 190-

  Rudin, Dan ^a  

^a King's Daughter Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GABEXATE; SOMATOSTATIN;

CLINICAL PRACTICE; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; HUMAN; HYPERAMYLASEMIA; LETTER; METHODOLOGY; OUTCOME ASSESSMENT; OUTPATIENT; PANCREATITIS; PRIORITY JOURNAL; RISK REDUCTION;

CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; GABEXATE; HUMANS; INJECTIONS; PANCREATITIS; SERINE PROTEINASE INHIBITORS; SOMATOSTATIN;

EID: 37249006456     PISSN: 00165107     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gie.2007.07.038     Document Type: Letter

References (4)

1. Andriulli A., Leandro G., Federici T., et al. Prophylactic administration of somatostatin or gabexate does not prevent pancreatitis after ERCP: an updated meta-analysis. Gastrointest Endosc 65 (2007) 624-632
2. Rudin D., Kiss A., Wetz R.V., et al. Somatostatin and gabexate for post-endoscopic retrograde cholangiopancreatography pancreatitis prevention: meta-analysis of randomized placebo-controlled trials. J Gastroenterol Hepatol 22 (2007) 977-983
3. Andriulli A., Caruso N., Quitadamo M., et al. Antisecretory vs antiproteasic drugs in the prevention of post-ERCP pancreatitis: the evidence-based medicine derived from a meta-analysis study. JOP 4 (2003) 41-48
4. Andriulli A., Leandro G., Niro G., et al. Pharmacologic treatment can prevent pancreatic injury after ERCP: a meta-analysis. Gastrointest Endosc 51 (2000) 1-7